BMO Capital, Precision BioSciences
Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating ...
Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...
Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...
JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...
CFO John Alexander Kelly purchased 2,113 shares of Precision BioSciences stock in a transaction dated Friday, December 27th.
DURHAM, N.C., January 09, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Investing.com -- Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a Phase 1/2 clinical trial. The ...
Stifel Financial Corp cut its position in Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) by 30.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 21,270 shares of the company ...
2d
BMO Capital analyst Kostas Biliouris upgraded the rating on Precision BioSciences (DTIL – Research Report) to a Buy today, setting a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback